Skip to main content
. 2021 Oct 11;125(12):1647–1656. doi: 10.1038/s41416-021-01571-y

Fig. 5. Effects of a combination of 5-aza-dC and TBT on tumour growth.

Fig. 5

a Xenograft growth curves of the mock-, 5-aza-dC-, TBT- and combination-treated groups. A pre-treatment with 5-aza-dC induced significant suppression of tumour growth (P < 0.05). Results are shown as mean ± SE, and statistical significance was tested using an unpaired Student’s t-test (n = 5/vehicle group; n = 4/5-aza-dC group, n = 3/TBT group, n = 4/combination group). n.s. non-significant. b Macroscopic view of the xenografts in the four treatment groups. c The therapeutic effect assessed by tumour weight at necropsy. Horizontal bars show the average. The xenograft tumours in mock and 5-aza-dC monotherapy groups showed large variation in their size, but the combination of 5-aza-dC and TBT reduced the variation and showed small sizes. d Changes in bodyweight. Bodyweight was measured twice per week. There was no significant difference in bodyweight among the four treatment groups. e Effects on blood cell counts. WBC and RBC counts, along with hemoglobin level, were suppressed moderately by 5-aza-dC, but no further suppression was induced by the combination. Results are shown as mean ± SE (n = 5/vehicle group; n = 3/5-aza-dC group, n = 3/TBT group, n = 4/combination group). n.s. non-significant.